title: Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.
authors.affiliation: Clinical Research & Development, Department of Anesthesiology, University of Colorado Denver, Bioscience East, Suite 100, 1999 North Fitzsimons Parkway, Aurora, CO 80045-7503, USA.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Steudel
authors.forename: Colleen
authors.initials: C
authors.lastname: Dingmann
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Zhang
authors.forename: Jamie
authors.initials: J
authors.lastname: Bendrick-Peart
authors.forename: Claudia
authors.initials: C
authors.lastname: Clavijo
authors.forename: John
authors.initials: J
authors.lastname: Shulze
authors.forename: Ronald
authors.initials: R
authors.lastname: Betts
authors.forename: Uwe
authors.initials: U
authors.lastname: Christians
mesh_terms: D000328:Adult; D049109:Cell Proliferation / Q000187:drug effects; D002853:Chromatography, Liquid; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; C518022:umirolimus; D020123:Sirolimus